Early Phase 1 N=50 Advanced Comprehensive Diabetes Care for Veterans With Poorly-Controlled Diabetes
Diabetes
Primary: Diabetes Control — 10.7; 10.2; 10.3; 9.1 percentage of glycosylated hemoglobin — p=0.012
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 A Study to Evaluate the Effect of Lipid Infusion on Toll Like Receptor 4 (TLR4) Signaling
Diabetes · Obesity
Primary: Muscle Insulin Sensitivity-M Value — 9.9; 8.3 mg/kg.min
N/A N=299 A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) Time — 4.87 months
Phase 2 N=510 Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome
Acute Coronary Syndrome
Primary: Sensitivity, Specificity of Detecting Myocardial Ischemia (Reader 1) — 75.2; 67.7 % (n/N)
N/A N=50,343 Case-Control-Study on the Breast Cancer Risk of Mirena® Compared With Copper IUDs
Breast Cancer
Primary: Breast Cancer Risk — 1076; 1068 participants
Phase 3 N=28 Drug Combination on Exercise Performance at High Altitude
Acute Mountain Sickness
Primary: Time (Minutes) to Complete 2 Miles on a Treadmill — 1544; 1540 seconds
Phase 1 N=24 Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution
Healthy
Primary: Percentage of Subjects With Drug-related Adverse Events — 16.7; 44.4; 11.1 Percentage of participants
Phase 3 N=623 A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia
Schizophrenia
Primary: The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score — -20.9; -21.8; -9.8 units on a scale — p=<0.001
Phase 1 N=6 Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone
Multiple Myeloma
Primary: Number of Participants With Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, Deaths — 2; 3; 1; 3 participants
Phase 3 N=2,034 A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Progression-free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With…
Phase 2 N=65 Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene
Lung Cancer · Non-small Cell Lung Cancer · Bronchioloalveolar Cancer
Primary: The Radiographic Response to Gefitinib — 21 participants
N/A N=31 Seizure Detection and Automatic Magnet Mode Performance Study
Epilepsy
Primary: Summary of Seizures Reported by Investigators and Triple Review — 87; 124; 211; 82 Seizures
Phase 3 N=346 Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients
Idiopathic Parkinson's Disease
Primary: Absolute Change in Absolute Time Spent 'Off' From Baseline to the End of Double-blind Maintenance Period — -1.13; -2.36 hours — p==0.0002
N/A N=287 Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders
Bipolar Disorder · Schizophrenia · Major Depressive Disorder
Primary: Physical Health-related Quality of Life — 34.00; 33.61 units on a scale
Phase 2 N=24 Phase II Study of Digitoxin to Treat Cystic Fibrosis
Cystic Fibrosis
Primary: Effect of Digitoxin on IL-8 (Interleukin 8) in Induced Sputum in Stable Cystic Fibrosis (CF) Patients. — 4.59; 4.96; 5.04; 4.94 log 10 (pg/mL) — p=>0.05